donate corporate_partners web_sponsors contact_us press_room
banner
  Breast Cancer Menopause & Women's Health Ending Breast Cancer Clinicians & Researchers
  search
advanced_search
Prevention
High Risk
Cancer Recurrence
Survivors
Populations of Interest
Community & Connection
 
print
clippings
email
 
subscribe
Understanding Your Cancer Treatment Decisions Clinical Trials Expert Opinion Hot Topics In the News Your Questions
Newly Diagnosed / Treatment Decisions scissors
LCIS

What is lobular carcinoma in situ (LCIS)?
LCIS is a noninvasive precancer. Lobular means that the unusual cells are in the lobules, the parts of the breast capable of making milk. If you have LCIS it means that you have abnormal cells in the lining of a lobule. Even though LCIS contains the word carcinoma, which means "cancer," LCIS is not cancer and it is not life threatening.


[Enlarge image]

How is it treated?
Basically this is a prevention situation: You want to prevent yourself from ever getting breast cancer. There are a number of options. What's important is that you give yourself the time to figure out what you want to do. LCIS doesn't call for an immediate decision. LCIS is a risk factor for subsequent cancer, not cancer itself. There is no rush to begin a treatment.

The National Comprehensive Cancer Network treatment guidelines recommend close follow-up for women with LCIS. If possible, this should be done at a program for high-risk women. These programs provide close follow-up, which means clinical breast exams every six months and yearly mammograms. That way if a cancer does develop, you're likely to catch it at an early stage and can decide then if you want to have a mastectomy, or a lumpectomy and radiation.

More controversial is the question of taking tamoxifen for five years to prevent the subsequent development of breast cancer. Tamoxifen is a hormone therapy used to treat women with breast cancer who have hormone-sensitive tumors. It has been shown to decrease the chance of getting breast cancer by 56 percent in women with LCIS. This means that the risk becomes 56 percent of the original risk. The original risk is 1 percent per year, so taking tamoxifen would reduce your risk to .5 percent a year.

The most drastic option is bilateral prophylactic mastectomy. Why bilateral (both breasts)? Because if you have LCIS you have a risk of getting breast cancer in either breast, not just the breast in which the LCIS is found. Some women choose this because they want to know they've done everything they could. They feel that if they get breast cancer, at least it isn't their fault, whereas if they hadn't done anything surgically and gotten the disease, they'd always wonder if they could have prevented it. The reason this is considered drastic is that most women with LCIS will never go on to develop breast cancer.